Stockscreener 앱 받기
2.21
5.96%
-0.14
전일 마감가:
$2.35
열려 있는:
$2.34
하루 거래량:
6.19M
Relative Volume:
0.70
시가총액:
$667.22M
수익:
$188.87M
순이익/손실:
$-400.38M
주가수익비율:
-1.4733
EPS:
-1.5
순현금흐름:
$-260.90M
1주 성능:
+13.92%
1개월 성능:
+9.41%
6개월 성능:
+48.32%
1년 성능:
+38.12%
1일 변동 폭
$2.205
$2.40
1주일 범위
$1.84
$2.40
52주 변동 폭
$0.8511
$2.725
퍼시픽 바이오 사이언스 Stock (PACB) Company Profile
명칭
Pacific Biosciences Of California Inc
전화
650-521-8000
주소
1305 O'BRIEN DRIVE, MENLO PARK, CA
PACB을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PACB
Pacific Biosciences Of California Inc
|
2.21 | 709.48M | 188.87M | -400.38M | -260.90M | -1.50 |
|
ABT
Abbott Laboratories
|
121.76 | 214.80B | 43.84B | 13.90B | 6.92B | 7.9725 |
|
SYK
Stryker Corp
|
363.78 | 138.62B | 24.38B | 2.94B | 4.07B | 7.6159 |
|
BSX
Boston Scientific Corp
|
88.07 | 133.46B | 19.35B | 2.78B | 3.82B | 1.8696 |
|
MDT
Medtronic Plc
|
96.76 | 126.92B | 34.76B | 4.79B | 5.21B | 3.7017 |
|
EW
Edwards Lifesciences Corp
|
84.35 | 49.03B | 5.88B | 1.34B | 799.60M | 2.3489 |
퍼시픽 바이오 사이언스 Stock (PACB) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-11-11 | 다운그레이드 | UBS | Buy → Neutral |
| 2024-06-03 | 재개 | Jefferies | Buy |
| 2024-04-22 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2024-04-18 | 다운그레이드 | Goldman | Buy → Neutral |
| 2023-12-14 | 개시 | Guggenheim | Neutral |
| 2023-12-14 | 개시 | Stephens | Overweight |
| 2023-12-13 | 개시 | Wolfe Research | Peer Perform |
| 2023-11-17 | 업그레이드 | UBS | Neutral → Buy |
| 2023-10-31 | 업그레이드 | Cantor Fitzgerald | Neutral → Overweight |
| 2023-09-28 | 개시 | Bernstein | Outperform |
| 2023-07-05 | 재개 | JP Morgan | Overweight |
| 2023-06-30 | 개시 | Goldman | Buy |
| 2023-05-10 | 개시 | Barclays | Equal Weight |
| 2023-03-31 | 업그레이드 | TD Cowen | Market Perform → Outperform |
| 2023-02-02 | 개시 | UBS | Neutral |
| 2023-01-20 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2023-01-05 | 개시 | Scotiabank | Sector Outperform |
| 2022-01-21 | 재개 | Cantor Fitzgerald | Overweight |
| 2022-01-06 | 재개 | Piper Sandler | Neutral |
| 2021-10-15 | 재개 | Cowen | Market Perform |
| 2021-09-27 | 개시 | Canaccord Genuity | Buy |
| 2021-02-11 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2020-11-03 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2020-10-02 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2020-09-09 | 개시 | Morgan Stanley | Equal-Weight |
| 2020-06-02 | 재개 | Cantor Fitzgerald | Overweight |
| 2020-03-09 | 재개 | Cantor Fitzgerald | Overweight |
| 2019-10-15 | 업그레이드 | Piper Jaffray | Neutral → Overweight |
| 2019-04-02 | 다운그레이드 | Stephens | Overweight → Equal-Weight |
| 2018-10-19 | 개시 | Cowen | Outperform |
| 2017-11-03 | 다운그레이드 | First Analysis Sec | Overweight → Equal-Weight |
| 2017-09-28 | 다운그레이드 | CL King | Buy → Neutral |
| 2016-11-03 | 재확인 | Cantor Fitzgerald | Buy |
| 2016-06-27 | 개시 | CL King | Buy |
| 2016-04-15 | 개시 | First Analysis Sec | Overweight |
| 2016-02-04 | 다운그레이드 | Piper Jaffray | Overweight → Neutral |
| 2016-01-04 | 재확인 | Cantor Fitzgerald | Buy |
| 2015-10-23 | 업그레이드 | Piper Jaffray | Neutral → Overweight |
| 2015-08-27 | 개시 | Cantor Fitzgerald | Buy |
| 2015-02-04 | 재확인 | Maxim Group | Buy |
| 2013-09-26 | 재확인 | Maxim Group | Buy |
| 2013-01-14 | 재확인 | Maxim Group | Buy |
모두보기
퍼시픽 바이오 사이언스 주식(PACB)의 최신 뉴스
Pacific Biosciences of California (PACB) Dips More Than Broader Market: What You Should Know - sharewise.com
Pacific Biosciences Shares Gain Momentum on Strong Preliminary Results and Clinical Adoption - AD HOC NEWS
Pacific Biosciences of California (NASDAQ:PACB) Shares Down 6.6%Time to Sell? - MarketBeat
Pacific Biosciences of California, Inc.'s (NASDAQ:PACB) High Institutional Ownership Speaks for Itself as Stock Continues to Impress, up 11% Over Last Week - 富途牛牛
PacBio Stock Up on HiFi Sequencing Adoption for Major SUDC Research - Yahoo Finance
Pacific Biosciences of California (NASDAQ:PACB) Trading 6.2% HigherStill a Buy? - MarketBeat
Canada Next-Generation Sequencing (NGS) Market Analysis and - GlobeNewswire
Canada Next-Generation Sequencing (NGS) Market Analysis and Forecast, 2025-2035, Featuring Illumina, Oxford Nanopore Technologies, Pacific Bioscience of California, MGI Tech Co., QIAGEN and More - Yahoo Finance
Pacific Biosciences stock gets Buy rating reiteration from Canaccord By Investing.com - Investing.com Canada
Pacific Biosciences' Preliminary Q4 Revenue Climb 14% On DNA Sequencing System Sales - Nasdaq
PACB: Clinical adoption and SPRQ innovation drive growth, with Europe leading and costs dropping - TradingView — Track All Markets
PACB: Clinical growth, Spark Chemistry, and record consumables drive robust momentum into 2026 - TradingView — Track All Markets
PacBio plans collaboration on rare disease therapies with n-Lorem By Investing.com - Investing.com Canada
PacBio (PACB) Advances Childhood Death Research with HiFi Genome Sequencing - GuruFocus
PACB Forecasts Strong FY25 Revenue as Sales Gain Traction - GuruFocus
PacBio Announces Proposed Collaboration with n-Lorem Foundation and EspeRare to Advance Antisense Oligonucleotide Therapies for Rare Genetic Diseases - Quiver Quantitative
PacBio to Support Research on Sudden Unexplained Death in Childhood Using HiFi Whole-Genome Sequencing - Quiver Quantitative
PacBio Announces Plans for Collaboration With n-Lorem Foundation and EspeRare to Advance Precision Therapies for Rare Genetic Diseases - marketscreener.com
PacBio HiFi Adopted as First-Line Sequencing Approach to Investigate Sudden Unexplained Death in Childhood (SUDC) - marketscreener.com
PacBio HiFi Announces it has Adopted as First-Line Sequencing Approach to Investigate Sudden Unexplained Death in Childhood - marketscreener.com
Here's Why You Should Add PacBio Stock to Your Portfolio Now - MSN
How PacBio (PACB) Is Seeing Its Fair Value Story Shift After ARK’s Share Purchase - Yahoo Finance
PacBio stock dips post latest launch to expand multiomics capabilities - MSN
HOKA Shopping Guide: Can Pacific Biosciences of California Inc. stock double in next 5 years - ulpravda.ru
PacBio Stock Dips Post Latest Launch to Expand Multiomics Capabilities - sharewise.com
Can PacBio’s New CiFi Method Reshape PACB’s Innovation Story and Recurring Revenue Potential? - Yahoo Finance
Can Pacific Biosciences of California Inc. stock deliver consistent earnings growthOptions Play & Short-Term High Return Strategies - ulpravda.ru
Here's why you should add PacBio stock to your portfolio - MSN
What insider trading reveals about Pacific Biosciences of California Inc. stockTrade Exit Summary & Smart Investment Allocation Tips - Улправда
How Pacific Biosciences of California Inc. (P09) stock trades after rate cutsPortfolio Update Report & Reliable Entry Point Alerts - ulpravda.ru
Is Pacific Biosciences of California Inc. stock a defensive play in 20252025 Earnings Impact & Daily Growth Stock Investment Tips - Улправда
What technical charts say about Pacific Biosciences of California Inc. stockJuly 2025 Closing Moves & Free Weekly Watchlist of Top Performers - Улправда
Can Pacific Biosciences of California Inc. stock double in next 5 yearsJuly 2025 Highlights & AI Powered Buy and Sell Recommendations - ulpravda.ru
PacBio and UC Davis Researchers Introduce CiFi, A New Long-Read 3C Method That Enables Chromosome-Scale Assemblies from A Single SMRT Cell - marketscreener.com
PacBio introduces CiFi method for chromosome-scale genome assembly By Investing.com - Investing.com Canada
PacBio Introduces CiFi: A Breakthrough Method for Chromosome-Scale Genome Assemblies from Limited Sample Material - Quiver Quantitative
PacBio and UC Davis Researchers Introduce CiFi, a New Long-Read 3C Method That Enables Chromosome-Scale Assemblies from a Single SMRT Cell - marketscreener.com
New DNA mapping method builds full chromosomes from tiny samples - Stock Titan
Will Pacific Biosciences of California Inc. (P09) stock justify high valuationFed Meeting & Expert Curated Trade Ideas - ulpravda.ru
Barclays analyst is bullish on Pacific Biosciences of California, Inc. (PACB) - MSN
Pacific Biosciences of California, Inc. (NASDAQ:PACB) Given Consensus Rating of "Hold" by Brokerages - MarketBeat
Pacific Biosciences of California (PACB) Gains As Market Dips: What You Should Know - sharewise.com
Here's Why You Should Add PacBio Stock to Your Portfolio - Yahoo Finance
PACB (Pacific Biosciences of California) Land And Improveme - GuruFocus
What analysts say about Pacific Biosciences of California Inc stockOptions Trading Strategies & Low Entry Cost Trading - earlytimes.in
Three Genomics Stocks Worth Tracking This Year - Nasdaq
We Think Pacific Biosciences of California (NASDAQ:PACB) Has A Fair Chunk Of Debt - simplywall.st
What drives Pacific Biosciences of California Inc P09 stock priceMarket Volatility Update & Missed Nvidia? Don’t Miss This One - earlytimes.in
Retail Surge: Will Pacific Biosciences of California Inc P09 stock rise with strong economyJuly 2025 Volume & Low Risk Entry Point Tips - moha.gov.vn
Stocks making big moves this week: PacBio, Crocs, FuelCell Energy, AMC Entertainment, and ON24 - The Globe and Mail
PacBio (PACB) Stock Is Up, What You Need To Know - Finviz
퍼시픽 바이오 사이언스 (PACB) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.42%
1.96%
자본화:
|
볼륨(24시간):